Because of our in-house panel, we are the most trusted partner in identifying, mapping, and engaging KOLs in the life sciences and healthcare sectors.
Because their recommendations on pharmaceuticals and devices are founded on solid research, key opinion leaders(KOL) are the perfect drivers for any healthcare product firm (drugs, gadgets, diagnostics).
At SGA, we work with our customers to find the kind of key opinion leader (KOL) to advise them on the best ways to network within their business. It can result in a more extensive disease environment within which the client's treatment or technology must function.
SGA's panel of KOLs spans more than 30 sub-specialties and 15 organizational levels, from chief executive officers to senior managers and distributors. Our panelists provide invaluable insight into the market's mood, perspective, and anticipations throughout a client's product's lifetime and clinical trials. Our bilingual analysts will facilitate communication with these key opinion leaders in both English- and non-English-speaking areas.
Why SGA
Industry leaders
SGA thrives by its brand promise Lifes Possible and is recognized as the trusted life sciences & healthcare business consulting and services provider company in the U.S.
12+ Languages
Multilingual capabilities include Mandarin, Cantonese, Korean, German, Spanish, Arabic, Bahasa, Hindi, Bengali, and English (U.S. & U.K.) experts (either in-house or partnerships).
Data-Driven Insights
With in-depth domain knowledge and proven capabilities of delivering monetizable insights, we deliver high-quality, efficient outputs.
End-To-End Solutioning
The in-house KOL capability of more than 700, along with in-house capabilities of primary market research, financial research, data analytics, engineering, IT, and ESG research and consulting, helps to present credible competitive information.
White Papers
Emergence of Novel Immune - Mediated Therapies
Immunotherapy has emerged as a promising treatment for cancer, with immune checkpoint inhibitors (ICIs) dominating the market. The market is projected to...
White Papers
Future Trends and Technological Advances in Vaccine Treatment and Disease Prevention
The introduction of vaccines for key diseases, such as meningococcal meningitis A, hepatitis E, and malaria, in recent years has helped to reduce mortality...
White Papers
Market Entry in 2023: Why Must You Also Look at Markets Other Than the US and Japan?
Due to dollar fluctuations and the likelihood of market recession, investors and manufacturers of medical devices and pharma are exploring new opportunities...
CASE STUDIES
We strongly believe in equal opportunity for all. Our research team consists of more females than males i.e., 55 % females, and consists of PhDs, M Pharms, D Pharms, Postgraduate in finance, Biotech postgraduates, and MBAs.
